Dexamethasone Treatment Considerably Reduces the Levels of Some Inflammatory Cytokines, Lactate Dehydrogenase, and C-Reactive Protein in COVID-19 Pneumonia Patients With Pre-existing COPD
Background: Dexamethasone is the most widely used corticosteroid for treating COVID-19 pulmonary complications. The effects of dexamethasone on serum inflammatory factors, including C-reactive protein (CRP), lactate dehydrogenase (LDH), and cortisol, were evaluated in COVID-19 pneumonia patients wit...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Kerman University of Medical Sciences
2024-10-01
|
| Series: | Journal of Kerman University of Medical Sciences |
| Subjects: | |
| Online Access: | https://jkmu.kmu.ac.ir/article_92258_c596ba0c22ae9cc1147fb7cdd650caf8.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850034638191329280 |
|---|---|
| author | Gholamreza Sepehri Zeinab Fallah Mitra Samareh Fekri Behnam Dalfardi Shahriar Dabiri Hamid Daneshvar Mohammad Javad Najafzadeh |
| author_facet | Gholamreza Sepehri Zeinab Fallah Mitra Samareh Fekri Behnam Dalfardi Shahriar Dabiri Hamid Daneshvar Mohammad Javad Najafzadeh |
| author_sort | Gholamreza Sepehri |
| collection | DOAJ |
| description | Background: Dexamethasone is the most widely used corticosteroid for treating COVID-19 pulmonary complications. The effects of dexamethasone on serum inflammatory factors, including C-reactive protein (CRP), lactate dehydrogenase (LDH), and cortisol, were evaluated in COVID-19 pneumonia patients with pre-existing chronic obstructive pulmonary disease (COPD) in this study.Methods: A total of 36 COVID-19 patients with pneumonia who had pre-existing COPD and were critically ill and 56 COVID-19- positive patients without pre-existing COPD were selected. A daily dose of 6–8 mg dexamethasone was administered during the hospitalization period. Some inflammatory markers (TNF-α, IL-10, and IL-6) and the serum levels of cortisol, LDH, and CRP were measured on admission and one week after hospitalization.Results: TNF-α and IL-6 concentrations were significantly reduced and IL-10 significantly increased in all COVID-19 pneumonia patients with or without pre-existing COPD as a result of a daily dose of dexamethasone. Also, a significant reduction in cortisol, CRP, and LDH was observed following dexamethasone administration in all COVID-19 pneumonia patients, with or without preexisting COPD, with no correlation with gender, cigarette or waterpipe smoking, or opium abuse.Conclusion: Our results showed a significant increase in TNF-α, IL-6, IL-10, cortisol, LDH, and CRP and a significant reduction in IL-10 in all critically ill COVID-19 pneumonia patients. Dexamethasone administration significantly reduced cortisol and proinflammatory cytokines and also LDH and CRP as the markers of COVID-19 severity. |
| format | Article |
| id | doaj-art-ca6b1c96834f4ef1a3209d76e1955d29 |
| institution | DOAJ |
| issn | 1023-9510 2008-2843 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | Kerman University of Medical Sciences |
| record_format | Article |
| series | Journal of Kerman University of Medical Sciences |
| spelling | doaj-art-ca6b1c96834f4ef1a3209d76e1955d292025-08-20T02:57:45ZengKerman University of Medical SciencesJournal of Kerman University of Medical Sciences1023-95102008-28432024-10-0131525926510.34172/jkmu.2024.4092258Dexamethasone Treatment Considerably Reduces the Levels of Some Inflammatory Cytokines, Lactate Dehydrogenase, and C-Reactive Protein in COVID-19 Pneumonia Patients With Pre-existing COPDGholamreza Sepehri0Zeinab Fallah1Mitra Samareh Fekri2Behnam Dalfardi3Shahriar Dabiri4Hamid Daneshvar5Mohammad Javad Najafzadeh6Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, IranCardiovascular Research Center, Kerman University of Medical Sciences, Kerman, IranPhysiology Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, IranDepartment of Internal Medicine, Afzalipour Hospital, Faculty of Medicine, Kerman University of Medical Sciences, Kerman, IranDepartment of Pathology, Faculty of Medicine, Kerman University of Medical Sciences, Kerman, IranImmunology Department, Faculty of Medicine, Kerman University of Medical Sciences, Kerman, IranDepartment of Physiology- Pharmacology, Faculty of Medicine, Kerman University of Medical Sciences, Kerman, IranBackground: Dexamethasone is the most widely used corticosteroid for treating COVID-19 pulmonary complications. The effects of dexamethasone on serum inflammatory factors, including C-reactive protein (CRP), lactate dehydrogenase (LDH), and cortisol, were evaluated in COVID-19 pneumonia patients with pre-existing chronic obstructive pulmonary disease (COPD) in this study.Methods: A total of 36 COVID-19 patients with pneumonia who had pre-existing COPD and were critically ill and 56 COVID-19- positive patients without pre-existing COPD were selected. A daily dose of 6–8 mg dexamethasone was administered during the hospitalization period. Some inflammatory markers (TNF-α, IL-10, and IL-6) and the serum levels of cortisol, LDH, and CRP were measured on admission and one week after hospitalization.Results: TNF-α and IL-6 concentrations were significantly reduced and IL-10 significantly increased in all COVID-19 pneumonia patients with or without pre-existing COPD as a result of a daily dose of dexamethasone. Also, a significant reduction in cortisol, CRP, and LDH was observed following dexamethasone administration in all COVID-19 pneumonia patients, with or without preexisting COPD, with no correlation with gender, cigarette or waterpipe smoking, or opium abuse.Conclusion: Our results showed a significant increase in TNF-α, IL-6, IL-10, cortisol, LDH, and CRP and a significant reduction in IL-10 in all critically ill COVID-19 pneumonia patients. Dexamethasone administration significantly reduced cortisol and proinflammatory cytokines and also LDH and CRP as the markers of COVID-19 severity.https://jkmu.kmu.ac.ir/article_92258_c596ba0c22ae9cc1147fb7cdd650caf8.pdfcovid-19copddexamethasoneinflammatory cytokinescortisolc-reactive proteinlactate dehydrogenase |
| spellingShingle | Gholamreza Sepehri Zeinab Fallah Mitra Samareh Fekri Behnam Dalfardi Shahriar Dabiri Hamid Daneshvar Mohammad Javad Najafzadeh Dexamethasone Treatment Considerably Reduces the Levels of Some Inflammatory Cytokines, Lactate Dehydrogenase, and C-Reactive Protein in COVID-19 Pneumonia Patients With Pre-existing COPD Journal of Kerman University of Medical Sciences covid-19 copd dexamethasone inflammatory cytokines cortisol c-reactive protein lactate dehydrogenase |
| title | Dexamethasone Treatment Considerably Reduces the Levels of Some Inflammatory Cytokines, Lactate Dehydrogenase, and C-Reactive Protein in COVID-19 Pneumonia Patients With Pre-existing COPD |
| title_full | Dexamethasone Treatment Considerably Reduces the Levels of Some Inflammatory Cytokines, Lactate Dehydrogenase, and C-Reactive Protein in COVID-19 Pneumonia Patients With Pre-existing COPD |
| title_fullStr | Dexamethasone Treatment Considerably Reduces the Levels of Some Inflammatory Cytokines, Lactate Dehydrogenase, and C-Reactive Protein in COVID-19 Pneumonia Patients With Pre-existing COPD |
| title_full_unstemmed | Dexamethasone Treatment Considerably Reduces the Levels of Some Inflammatory Cytokines, Lactate Dehydrogenase, and C-Reactive Protein in COVID-19 Pneumonia Patients With Pre-existing COPD |
| title_short | Dexamethasone Treatment Considerably Reduces the Levels of Some Inflammatory Cytokines, Lactate Dehydrogenase, and C-Reactive Protein in COVID-19 Pneumonia Patients With Pre-existing COPD |
| title_sort | dexamethasone treatment considerably reduces the levels of some inflammatory cytokines lactate dehydrogenase and c reactive protein in covid 19 pneumonia patients with pre existing copd |
| topic | covid-19 copd dexamethasone inflammatory cytokines cortisol c-reactive protein lactate dehydrogenase |
| url | https://jkmu.kmu.ac.ir/article_92258_c596ba0c22ae9cc1147fb7cdd650caf8.pdf |
| work_keys_str_mv | AT gholamrezasepehri dexamethasonetreatmentconsiderablyreducesthelevelsofsomeinflammatorycytokineslactatedehydrogenaseandcreactiveproteinincovid19pneumoniapatientswithpreexistingcopd AT zeinabfallah dexamethasonetreatmentconsiderablyreducesthelevelsofsomeinflammatorycytokineslactatedehydrogenaseandcreactiveproteinincovid19pneumoniapatientswithpreexistingcopd AT mitrasamarehfekri dexamethasonetreatmentconsiderablyreducesthelevelsofsomeinflammatorycytokineslactatedehydrogenaseandcreactiveproteinincovid19pneumoniapatientswithpreexistingcopd AT behnamdalfardi dexamethasonetreatmentconsiderablyreducesthelevelsofsomeinflammatorycytokineslactatedehydrogenaseandcreactiveproteinincovid19pneumoniapatientswithpreexistingcopd AT shahriardabiri dexamethasonetreatmentconsiderablyreducesthelevelsofsomeinflammatorycytokineslactatedehydrogenaseandcreactiveproteinincovid19pneumoniapatientswithpreexistingcopd AT hamiddaneshvar dexamethasonetreatmentconsiderablyreducesthelevelsofsomeinflammatorycytokineslactatedehydrogenaseandcreactiveproteinincovid19pneumoniapatientswithpreexistingcopd AT mohammadjavadnajafzadeh dexamethasonetreatmentconsiderablyreducesthelevelsofsomeinflammatorycytokineslactatedehydrogenaseandcreactiveproteinincovid19pneumoniapatientswithpreexistingcopd |